 David Kroll
Concepts (443)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| DNA Topoisomerases, Type II | 10 | 2005 | 44 | 1.230 |
Why?
| | Antineoplastic Agents, Phytogenic | 16 | 2012 | 181 | 1.170 |
Why?
| | Plant Extracts | 10 | 2010 | 154 | 0.860 |
Why?
| | Silymarin | 10 | 2016 | 194 | 0.770 |
Why?
| | Phytotherapy | 7 | 2010 | 66 | 0.660 |
Why?
| | Antineoplastic Agents | 13 | 2016 | 1879 | 0.570 |
Why?
| | Prostatic Neoplasms | 10 | 2016 | 921 | 0.540 |
Why?
| | Isoenzymes | 4 | 2001 | 283 | 0.460 |
Why?
| | Camptothecin | 4 | 2009 | 96 | 0.430 |
Why?
| | Flavonolignans | 4 | 2009 | 10 | 0.430 |
Why?
| | Hypocreales | 4 | 2013 | 8 | 0.410 |
Why?
| | Drug Interactions | 5 | 2010 | 338 | 0.410 |
Why?
| | Etoposide | 3 | 2001 | 148 | 0.400 |
Why?
| | Drug Screening Assays, Antitumor | 16 | 2013 | 180 | 0.390 |
Why?
| | Tumor Cells, Cultured | 9 | 2006 | 849 | 0.370 |
Why?
| | Transcriptional Activation | 4 | 1997 | 337 | 0.360 |
Why?
| | Plants, Medicinal | 6 | 2009 | 19 | 0.360 |
Why?
| | DNA | 9 | 2001 | 1352 | 0.310 |
Why?
| | Molecular Structure | 15 | 2013 | 434 | 0.300 |
Why?
| | Anti-Bacterial Agents | 6 | 2013 | 1481 | 0.300 |
Why?
| | Paclitaxel | 2 | 2009 | 190 | 0.280 |
Why?
| | Cell Line, Tumor | 19 | 2016 | 2710 | 0.280 |
Why?
| | Biological Products | 3 | 2012 | 166 | 0.280 |
Why?
| | Enzyme Inhibitors | 3 | 2012 | 750 | 0.280 |
Why?
| | Promoter Regions, Genetic | 4 | 2005 | 1131 | 0.260 |
Why?
| | Terminology as Topic | 1 | 2007 | 187 | 0.260 |
Why?
| | Topoisomerase II Inhibitors | 2 | 2005 | 23 | 0.250 |
Why?
| | Plant Proteins | 2 | 2004 | 81 | 0.240 |
Why?
| | Butyrates | 2 | 2001 | 53 | 0.220 |
Why?
| | Colchicum | 3 | 2010 | 3 | 0.220 |
Why?
| | Peptaibols | 2 | 2013 | 2 | 0.210 |
Why?
| | Terphenyl Compounds | 2 | 2013 | 3 | 0.210 |
Why?
| | DNA-Binding Proteins | 5 | 2005 | 1314 | 0.210 |
Why?
| | Indole Alkaloids | 2 | 2012 | 9 | 0.210 |
Why?
| | Antigens, Neoplasm | 5 | 2005 | 222 | 0.210 |
Why?
| | Transfection | 5 | 2000 | 866 | 0.200 |
Why?
| | Sesquiterpenes | 2 | 2013 | 51 | 0.200 |
Why?
| | Antifungal Agents | 2 | 2013 | 128 | 0.200 |
Why?
| | Hypericum | 1 | 2001 | 1 | 0.200 |
Why?
| | Herbal Medicine | 1 | 2001 | 4 | 0.200 |
Why?
| | Terpenes | 1 | 2001 | 21 | 0.190 |
Why?
| | Mixed Function Oxygenases | 1 | 2001 | 36 | 0.190 |
Why?
| | Benzene | 1 | 2001 | 13 | 0.190 |
Why?
| | Drug Carriers | 3 | 1998 | 112 | 0.190 |
Why?
| | Biomedical Research | 1 | 2007 | 585 | 0.190 |
Why?
| | Hemostasis | 1 | 2001 | 67 | 0.190 |
Why?
| | Thylakoids | 1 | 2001 | 4 | 0.190 |
Why?
| | Cytochrome P-450 Enzyme System | 1 | 2001 | 108 | 0.190 |
Why?
| | Aryl Hydrocarbon Hydroxylases | 2 | 2012 | 41 | 0.190 |
Why?
| | Neoplasms | 4 | 2009 | 2097 | 0.190 |
Why?
| | Genes, Plant | 1 | 2001 | 43 | 0.190 |
Why?
| | Antioxidants | 4 | 2016 | 530 | 0.180 |
Why?
| | Gene Expression Regulation, Enzymologic | 3 | 2008 | 270 | 0.180 |
Why?
| | Dietary Supplements | 1 | 2004 | 460 | 0.180 |
Why?
| | Dose-Response Relationship, Drug | 7 | 2012 | 1842 | 0.180 |
Why?
| | NF-kappa B | 4 | 2012 | 641 | 0.180 |
Why?
| | Liposomes | 2 | 1998 | 146 | 0.180 |
Why?
| | Arabidopsis Proteins | 1 | 2001 | 65 | 0.180 |
Why?
| | Arabidopsis | 1 | 2001 | 79 | 0.170 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2001 | 198 | 0.170 |
Why?
| | Proto-Oncogene Proteins c-akt | 3 | 2016 | 398 | 0.170 |
Why?
| | Ericales | 1 | 1999 | 2 | 0.160 |
Why?
| | Diterpenes | 3 | 2009 | 31 | 0.160 |
Why?
| | Humans | 54 | 2016 | 114654 | 0.160 |
Why?
| | Cell Cycle Proteins | 3 | 2008 | 551 | 0.160 |
Why?
| | Theophylline | 1 | 1999 | 60 | 0.160 |
Why?
| | Nuclear Magnetic Resonance, Biomolecular | 8 | 2013 | 238 | 0.160 |
Why?
| | Magnoliopsida | 1 | 1998 | 27 | 0.160 |
Why?
| | Annonaceae | 2 | 2009 | 4 | 0.150 |
Why?
| | Receptors, Androgen | 2 | 2010 | 131 | 0.150 |
Why?
| | beta-Galactosidase | 1 | 1997 | 62 | 0.150 |
Why?
| | Nuclear Proteins | 3 | 2007 | 591 | 0.150 |
Why?
| | Bronchodilator Agents | 1 | 1999 | 239 | 0.140 |
Why?
| | Cloning, Molecular | 2 | 2001 | 522 | 0.140 |
Why?
| | Enhancer of Zeste Homolog 2 Protein | 1 | 2016 | 37 | 0.140 |
Why?
| | Practice Guidelines as Topic | 1 | 2004 | 1394 | 0.140 |
Why?
| | Transcription Factors | 5 | 2016 | 1528 | 0.130 |
Why?
| | Fungi | 3 | 2011 | 124 | 0.130 |
Why?
| | Polycomb Repressive Complex 2 | 1 | 2016 | 59 | 0.130 |
Why?
| | Colchicine | 2 | 2006 | 24 | 0.130 |
Why?
| | Cyclic AMP Response Element-Binding Protein | 2 | 1993 | 127 | 0.130 |
Why?
| | Plasmids | 2 | 1993 | 343 | 0.120 |
Why?
| | Leukemia, Promyelocytic, Acute | 1 | 1995 | 12 | 0.120 |
Why?
| | HeLa Cells | 5 | 1997 | 562 | 0.120 |
Why?
| | Membrane Proteins | 1 | 2001 | 1018 | 0.120 |
Why?
| | Cell Cycle | 3 | 2007 | 542 | 0.120 |
Why?
| | COS Cells | 4 | 2000 | 175 | 0.120 |
Why?
| | Antiviral Agents | 2 | 2012 | 645 | 0.120 |
Why?
| | Lipids | 1 | 1998 | 580 | 0.120 |
Why?
| | Microbial Sensitivity Tests | 6 | 2013 | 300 | 0.120 |
Why?
| | Gene Expression | 2 | 2005 | 1421 | 0.120 |
Why?
| | Trans-Activators | 1 | 1997 | 367 | 0.120 |
Why?
| | Trichothecenes | 2 | 2011 | 4 | 0.110 |
Why?
| | Isocoumarins | 1 | 2013 | 1 | 0.110 |
Why?
| | Recombinant Fusion Proteins | 2 | 1993 | 616 | 0.110 |
Why?
| | Molecular Sequence Data | 7 | 2001 | 2785 | 0.110 |
Why?
| | Proto-Oncogene Proteins | 1 | 1997 | 608 | 0.110 |
Why?
| | Pyrrolidinones | 1 | 2013 | 25 | 0.110 |
Why?
| | Gene Expression Regulation, Neoplastic | 2 | 2016 | 1141 | 0.110 |
Why?
| | Aldehydes | 3 | 1999 | 138 | 0.110 |
Why?
| | Phosphodiesterase 4 Inhibitors | 1 | 2013 | 2 | 0.110 |
Why?
| | Cyclic Nucleotide Phosphodiesterases, Type 4 | 1 | 2013 | 6 | 0.110 |
Why?
| | Apoptosis | 4 | 2010 | 2362 | 0.110 |
Why?
| | Structure-Activity Relationship | 5 | 2012 | 502 | 0.100 |
Why?
| | Ascomycota | 1 | 2013 | 27 | 0.100 |
Why?
| | Drug Stability | 3 | 2009 | 151 | 0.100 |
Why?
| | Herb-Drug Interactions | 2 | 2009 | 4 | 0.100 |
Why?
| | Benzoquinones | 1 | 2013 | 44 | 0.100 |
Why?
| | Anthelmintics | 1 | 2012 | 9 | 0.100 |
Why?
| | Disulfides | 1 | 2012 | 90 | 0.100 |
Why?
| | Monocytes | 1 | 1995 | 502 | 0.100 |
Why?
| | Xanthones | 1 | 2011 | 2 | 0.100 |
Why?
| | Anthraquinones | 1 | 2011 | 9 | 0.100 |
Why?
| | Depsipeptides | 1 | 2011 | 13 | 0.100 |
Why?
| | Cyanobacteria | 1 | 2012 | 54 | 0.100 |
Why?
| | Cyclin-Dependent Kinases | 3 | 2008 | 111 | 0.100 |
Why?
| | Zearalenone | 1 | 2011 | 2 | 0.090 |
Why?
| | Hepacivirus | 1 | 2012 | 229 | 0.090 |
Why?
| | Drug Discovery | 1 | 2012 | 123 | 0.090 |
Why?
| | Lactones | 1 | 2011 | 54 | 0.090 |
Why?
| | Macrocyclic Compounds | 1 | 2010 | 9 | 0.090 |
Why?
| | Drug Evaluation, Preclinical | 2 | 2010 | 161 | 0.090 |
Why?
| | Piperazines | 1 | 2012 | 309 | 0.090 |
Why?
| | Animals | 20 | 2012 | 31698 | 0.090 |
Why?
| | Melanoma, Experimental | 1 | 1990 | 89 | 0.090 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 3 | 1997 | 318 | 0.080 |
Why?
| | Base Sequence | 6 | 1999 | 2114 | 0.080 |
Why?
| | Leukemia | 2 | 2001 | 209 | 0.080 |
Why?
| | Staphylococcus aureus | 1 | 2013 | 389 | 0.080 |
Why?
| | Ginkgo biloba | 1 | 2009 | 6 | 0.080 |
Why?
| | Acclimatization | 1 | 1990 | 149 | 0.080 |
Why?
| | Recombinant Proteins | 4 | 2009 | 1230 | 0.080 |
Why?
| | Amino Acid Sequence | 4 | 2001 | 1982 | 0.080 |
Why?
| | Plant Preparations | 1 | 2009 | 23 | 0.080 |
Why?
| | Warfarin | 1 | 2009 | 135 | 0.080 |
Why?
| | Hot Temperature | 1 | 1990 | 302 | 0.080 |
Why?
| | Echium | 1 | 2008 | 1 | 0.080 |
Why?
| | Pyrrolizidine Alkaloids | 1 | 2008 | 7 | 0.080 |
Why?
| | Glutathione Transferase | 2 | 1999 | 93 | 0.080 |
Why?
| | Chemical and Drug Induced Liver Injury | 1 | 2010 | 125 | 0.080 |
Why?
| | ErbB Receptors | 2 | 2012 | 554 | 0.080 |
Why?
| | Prostate-Specific Antigen | 2 | 2008 | 151 | 0.080 |
Why?
| | Mercuric Chloride | 1 | 1988 | 2 | 0.080 |
Why?
| | Protective Agents | 1 | 2008 | 37 | 0.080 |
Why?
| | Epoxide Hydrolases | 1 | 1988 | 10 | 0.080 |
Why?
| | Microsomes | 1 | 1988 | 24 | 0.080 |
Why?
| | Quaternary Ammonium Compounds | 2 | 1998 | 44 | 0.080 |
Why?
| | Immunoconjugates | 1 | 2009 | 87 | 0.080 |
Why?
| | Fatty Acids, Monounsaturated | 2 | 1998 | 47 | 0.080 |
Why?
| | Phosphorylation | 5 | 2016 | 1569 | 0.070 |
Why?
| | Hepatocytes | 1 | 2009 | 195 | 0.070 |
Why?
| | Proto-Oncogene Proteins c-mdm2 | 1 | 2008 | 56 | 0.070 |
Why?
| | Simaroubaceae | 1 | 2007 | 1 | 0.070 |
Why?
| | HL-60 Cells | 2 | 1997 | 28 | 0.070 |
Why?
| | Pharmacokinetics | 1 | 2007 | 25 | 0.070 |
Why?
| | Monosaccharides | 1 | 2007 | 11 | 0.070 |
Why?
| | Anthracenes | 1 | 2007 | 27 | 0.070 |
Why?
| | Herpesvirus 8, Human | 1 | 2007 | 61 | 0.070 |
Why?
| | Anti-Infective Agents | 1 | 2009 | 225 | 0.070 |
Why?
| | Dendrimers | 1 | 2006 | 13 | 0.070 |
Why?
| | Antibodies, Monoclonal | 2 | 2009 | 1262 | 0.070 |
Why?
| | Magnetic Resonance Spectroscopy | 4 | 2012 | 473 | 0.070 |
Why?
| | DNA, Neoplasm | 2 | 2001 | 157 | 0.070 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2010 | 256 | 0.070 |
Why?
| | Blotting, Western | 5 | 2008 | 1147 | 0.070 |
Why?
| | Anticarcinogenic Agents | 1 | 2007 | 67 | 0.070 |
Why?
| | Genes | 1 | 1987 | 223 | 0.070 |
Why?
| | Heat-Shock Proteins | 1 | 1987 | 113 | 0.070 |
Why?
| | Microsomes, Liver | 3 | 2012 | 55 | 0.070 |
Why?
| | Flavones | 1 | 2006 | 10 | 0.070 |
Why?
| | Calendula | 1 | 2006 | 1 | 0.070 |
Why?
| | Candida albicans | 3 | 2013 | 50 | 0.070 |
Why?
| | Case Management | 1 | 2006 | 62 | 0.070 |
Why?
| | Patient Dropouts | 1 | 2006 | 66 | 0.070 |
Why?
| | Models, Biological | 3 | 2008 | 1620 | 0.070 |
Why?
| | Purines | 1 | 2007 | 159 | 0.070 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2008 | 329 | 0.070 |
Why?
| | Protein Binding | 3 | 2001 | 1889 | 0.060 |
Why?
| | Chromatography, Affinity | 2 | 1997 | 80 | 0.060 |
Why?
| | Genetic Variation | 1 | 1990 | 870 | 0.060 |
Why?
| | Transcription, Genetic | 2 | 1993 | 1313 | 0.060 |
Why?
| | Anticoagulants | 1 | 2009 | 550 | 0.060 |
Why?
| | Liver | 2 | 2007 | 1637 | 0.060 |
Why?
| | Asteraceae | 1 | 2005 | 17 | 0.060 |
Why?
| | Cell Growth Processes | 1 | 2005 | 51 | 0.060 |
Why?
| | Neoplasms, Hormone-Dependent | 1 | 2005 | 38 | 0.060 |
Why?
| | Alkaloids | 1 | 2005 | 22 | 0.060 |
Why?
| | In Vitro Techniques | 3 | 2009 | 1016 | 0.060 |
Why?
| | Clinical Trials as Topic | 2 | 2006 | 931 | 0.060 |
Why?
| | Hypersensitivity, Delayed | 1 | 2004 | 27 | 0.060 |
Why?
| | Diospyros | 1 | 2004 | 1 | 0.060 |
Why?
| | Societies, Pharmaceutical | 1 | 2004 | 27 | 0.060 |
Why?
| | Naphthoquinones | 1 | 2004 | 17 | 0.060 |
Why?
| | Methylation | 2 | 2016 | 208 | 0.060 |
Why?
| | Carcinoma | 1 | 2006 | 198 | 0.060 |
Why?
| | Taxus | 1 | 2004 | 1 | 0.060 |
Why?
| | Camptotheca | 1 | 2004 | 1 | 0.060 |
Why?
| | Topoisomerase I Inhibitors | 1 | 2004 | 15 | 0.060 |
Why?
| | Deoxycytidine | 1 | 2004 | 138 | 0.060 |
Why?
| | Pharmaceutical Services | 1 | 2004 | 77 | 0.060 |
Why?
| | Cell Survival | 4 | 2012 | 1020 | 0.050 |
Why?
| | Leucine Zippers | 2 | 1993 | 16 | 0.050 |
Why?
| | Male | 14 | 2016 | 55579 | 0.050 |
Why?
| | Stereoisomerism | 3 | 2009 | 91 | 0.050 |
Why?
| | Proteins | 2 | 2000 | 908 | 0.050 |
Why?
| | History, 20th Century | 1 | 2004 | 264 | 0.050 |
Why?
| | Cell Proliferation | 4 | 2012 | 2186 | 0.050 |
Why?
| | Patient Selection | 1 | 2006 | 641 | 0.050 |
Why?
| | Patient Compliance | 1 | 2006 | 525 | 0.050 |
Why?
| | Membrane Potential, Mitochondrial | 2 | 2012 | 55 | 0.050 |
Why?
| | Phloroglucinol | 1 | 2001 | 1 | 0.050 |
Why?
| | Bridged Bicyclo Compounds | 1 | 2001 | 11 | 0.050 |
Why?
| | Drug Antagonism | 1 | 2001 | 8 | 0.050 |
Why?
| | Evidence-Based Medicine | 1 | 2006 | 668 | 0.050 |
Why?
| | Cytochrome P-450 CYP2C9 | 2 | 2012 | 17 | 0.050 |
Why?
| | Plastids | 1 | 2001 | 2 | 0.050 |
Why?
| | Eubacterium | 1 | 2001 | 3 | 0.050 |
Why?
| | Peptide Fragments | 2 | 1997 | 666 | 0.050 |
Why?
| | Cell Nucleus | 3 | 2010 | 554 | 0.050 |
Why?
| | Cytochrome P-450 CYP3A | 1 | 2001 | 61 | 0.050 |
Why?
| | Spectrophotometry, Ultraviolet | 2 | 2011 | 73 | 0.050 |
Why?
| | Kidney | 1 | 1988 | 1188 | 0.050 |
Why?
| | Escherichia coli | 3 | 1993 | 720 | 0.050 |
Why?
| | Carcinogens | 1 | 2001 | 103 | 0.050 |
Why?
| | DNA, Single-Stranded | 2 | 1993 | 111 | 0.050 |
Why?
| | Pharmacogenetics | 1 | 2001 | 149 | 0.040 |
Why?
| | Family Practice | 1 | 2004 | 427 | 0.040 |
Why?
| | Photosynthesis | 1 | 2001 | 75 | 0.040 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2001 | 353 | 0.040 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 2 | 2013 | 191 | 0.040 |
Why?
| | Carcinoma, Hepatocellular | 2 | 1999 | 211 | 0.040 |
Why?
| | Tyrosine 3-Monooxygenase | 1 | 2000 | 68 | 0.040 |
Why?
| | Biocompatible Materials | 2 | 2006 | 369 | 0.040 |
Why?
| | Detergents | 1 | 2000 | 41 | 0.040 |
Why?
| | Patient Education as Topic | 1 | 2004 | 680 | 0.040 |
Why?
| | Neoplasm Proteins | 2 | 2016 | 384 | 0.040 |
Why?
| | Glycosides | 2 | 2013 | 33 | 0.040 |
Why?
| | Serine Endopeptidases | 1 | 2000 | 102 | 0.040 |
Why?
| | Mass Screening | 1 | 2006 | 1004 | 0.040 |
Why?
| | Esters | 1 | 2000 | 61 | 0.040 |
Why?
| | Proteasome Endopeptidase Complex | 2 | 2011 | 133 | 0.040 |
Why?
| | Saccharomyces cerevisiae | 3 | 2009 | 476 | 0.040 |
Why?
| | Cation Exchange Resins | 1 | 1998 | 7 | 0.040 |
Why?
| | DNA Replication | 2 | 1997 | 202 | 0.040 |
Why?
| | Spectrometry, Mass, Electrospray Ionization | 2 | 2011 | 162 | 0.040 |
Why?
| | Arginine | 1 | 2000 | 238 | 0.040 |
Why?
| | Response Elements | 1 | 1999 | 82 | 0.040 |
Why?
| | Gentamicins | 1 | 1998 | 42 | 0.040 |
Why?
| | Regulatory Sequences, Nucleic Acid | 1 | 1998 | 81 | 0.040 |
Why?
| | Thymidine | 2 | 1995 | 58 | 0.040 |
Why?
| | Freezing | 1 | 1998 | 84 | 0.040 |
Why?
| | Polyesters | 1 | 1998 | 64 | 0.040 |
Why?
| | Cyclin-Dependent Kinase Inhibitor Proteins | 2 | 2008 | 7 | 0.040 |
Why?
| | Drug Costs | 1 | 1998 | 92 | 0.040 |
Why?
| | Cell Division | 2 | 1997 | 758 | 0.040 |
Why?
| | Trehalose | 1 | 1997 | 30 | 0.040 |
Why?
| | Signal Transduction | 1 | 2010 | 4512 | 0.040 |
Why?
| | Malondialdehyde | 1 | 1997 | 28 | 0.040 |
Why?
| | Scattering, Radiation | 1 | 1997 | 92 | 0.040 |
Why?
| | Enzyme Stability | 1 | 1997 | 62 | 0.040 |
Why?
| | Phosphatidylethanolamines | 1 | 1997 | 66 | 0.040 |
Why?
| | Freeze Drying | 1 | 1997 | 75 | 0.040 |
Why?
| | Plant Bark | 2 | 2009 | 11 | 0.040 |
Why?
| | Aspergillus niger | 2 | 2009 | 8 | 0.040 |
Why?
| | Indonesia | 2 | 2009 | 18 | 0.040 |
Why?
| | CCAAT-Enhancer-Binding Proteins | 1 | 1997 | 34 | 0.040 |
Why?
| | Sucrose | 1 | 1997 | 92 | 0.040 |
Why?
| | Proto-Oncogene Proteins c-myb | 1 | 1997 | 9 | 0.040 |
Why?
| | Dimerization | 1 | 1997 | 176 | 0.040 |
Why?
| | Histone Deacetylase 2 | 1 | 2016 | 7 | 0.040 |
Why?
| | Lipid Peroxidation | 1 | 1997 | 139 | 0.040 |
Why?
| | Protein Conformation | 2 | 1997 | 805 | 0.030 |
Why?
| | Histone Deacetylase 1 | 1 | 2016 | 16 | 0.030 |
Why?
| | Breast Neoplasms | 2 | 2006 | 1862 | 0.030 |
Why?
| | DNA (Cytosine-5-)-Methyltransferases | 1 | 2016 | 26 | 0.030 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2004 | 1355 | 0.030 |
Why?
| | Binding Sites | 2 | 1997 | 1168 | 0.030 |
Why?
| | Sequence Deletion | 1 | 1997 | 167 | 0.030 |
Why?
| | Enzyme Activation | 3 | 2007 | 785 | 0.030 |
Why?
| | Cytoplasm | 2 | 2008 | 255 | 0.030 |
Why?
| | Proto-Oncogene Proteins c-jun | 2 | 1993 | 47 | 0.030 |
Why?
| | KB Cells | 2 | 2007 | 4 | 0.030 |
Why?
| | Precipitin Tests | 2 | 1997 | 88 | 0.030 |
Why?
| | Jordan | 2 | 2006 | 3 | 0.030 |
Why?
| | Artemia | 2 | 2006 | 8 | 0.030 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2016 | 313 | 0.030 |
Why?
| | United States | 2 | 2004 | 12179 | 0.030 |
Why?
| | Drug Delivery Systems | 1 | 1998 | 296 | 0.030 |
Why?
| | Time Factors | 3 | 2008 | 6115 | 0.030 |
Why?
| | Proto-Oncogene Proteins c-fos | 2 | 1993 | 164 | 0.030 |
Why?
| | Butyric Acid | 1 | 1995 | 5 | 0.030 |
Why?
| | Female | 8 | 2013 | 59488 | 0.030 |
Why?
| | Light | 1 | 1997 | 336 | 0.030 |
Why?
| | Tetradecanoylphorbol Acetate | 1 | 1995 | 153 | 0.030 |
Why?
| | Genes, Reporter | 1 | 1995 | 257 | 0.030 |
Why?
| | Glioblastoma | 2 | 2007 | 253 | 0.030 |
Why?
| | Oxidation-Reduction | 1 | 1997 | 923 | 0.030 |
Why?
| | Kinetics | 1 | 1997 | 1551 | 0.030 |
Why?
| | Mice | 4 | 2012 | 14863 | 0.030 |
Why?
| | Bacteriophage T7 | 1 | 1993 | 3 | 0.030 |
Why?
| | Protein Sorting Signals | 1 | 1993 | 16 | 0.030 |
Why?
| | DNA, Recombinant | 1 | 1993 | 41 | 0.030 |
Why?
| | Depression | 1 | 2001 | 1134 | 0.030 |
Why?
| | Adenovirus E1A Proteins | 1 | 1993 | 11 | 0.030 |
Why?
| | Phenotype | 1 | 2001 | 2796 | 0.030 |
Why?
| | Kidney Tubules | 1 | 1994 | 107 | 0.030 |
Why?
| | DNA, Superhelical | 1 | 1993 | 11 | 0.030 |
Why?
| | Rats | 4 | 1999 | 4958 | 0.030 |
Why?
| | Nickel | 1 | 1993 | 50 | 0.030 |
Why?
| | Glucose | 1 | 1997 | 896 | 0.030 |
Why?
| | Epigenesis, Genetic | 1 | 2016 | 520 | 0.030 |
Why?
| | Haemonchus | 1 | 2012 | 1 | 0.030 |
Why?
| | Mutagenesis, Site-Directed | 1 | 1993 | 345 | 0.020 |
Why?
| | Optical Rotation | 1 | 2011 | 2 | 0.020 |
Why?
| | Histones | 1 | 2016 | 535 | 0.020 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2012 | 109 | 0.020 |
Why?
| | Spectrophotometry, Infrared | 1 | 2011 | 43 | 0.020 |
Why?
| | Crystallography, X-Ray | 1 | 2013 | 402 | 0.020 |
Why?
| | Resorcinols | 1 | 2011 | 4 | 0.020 |
Why?
| | Hydroxybenzoates | 1 | 2011 | 10 | 0.020 |
Why?
| | Transforming Growth Factor beta | 1 | 1994 | 448 | 0.020 |
Why?
| | RNA, Messenger | 1 | 1998 | 2552 | 0.020 |
Why?
| | Blood Proteins | 1 | 1993 | 231 | 0.020 |
Why?
| | Gene Expression Regulation | 2 | 1993 | 2319 | 0.020 |
Why?
| | Epitopes | 1 | 1993 | 435 | 0.020 |
Why?
| | Daunorubicin | 1 | 1990 | 24 | 0.020 |
Why?
| | Caspase 8 | 1 | 2010 | 43 | 0.020 |
Why?
| | Receptors, TNF-Related Apoptosis-Inducing Ligand | 1 | 2010 | 26 | 0.020 |
Why?
| | Protein Kinases | 1 | 1992 | 307 | 0.020 |
Why?
| | Drug Tolerance | 1 | 1990 | 79 | 0.020 |
Why?
| | Indoles | 1 | 2012 | 304 | 0.020 |
Why?
| | Transcription Factor RelA | 1 | 2010 | 82 | 0.020 |
Why?
| | Phosphates | 1 | 1991 | 159 | 0.020 |
Why?
| | Aporphines | 1 | 2009 | 1 | 0.020 |
Why?
| | Micrococcus luteus | 1 | 2009 | 3 | 0.020 |
Why?
| | Hydroxylation | 1 | 2009 | 29 | 0.020 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2011 | 470 | 0.020 |
Why?
| | Liver Function Tests | 1 | 2010 | 103 | 0.020 |
Why?
| | Spectrum Analysis | 1 | 2010 | 81 | 0.020 |
Why?
| | Placebos | 1 | 2010 | 197 | 0.020 |
Why?
| | Cell Culture Techniques | 1 | 2012 | 342 | 0.020 |
Why?
| | Inhibitory Concentration 50 | 1 | 2009 | 74 | 0.020 |
Why?
| | Mycobacterium tuberculosis | 1 | 2012 | 268 | 0.020 |
Why?
| | Doxorubicin | 1 | 1990 | 285 | 0.020 |
Why?
| | Antibody Specificity | 1 | 2009 | 176 | 0.020 |
Why?
| | Cell Line | 2 | 1994 | 2635 | 0.020 |
Why?
| | Proliferating Cell Nuclear Antigen | 1 | 2008 | 49 | 0.020 |
Why?
| | Bacteria | 2 | 2005 | 725 | 0.020 |
Why?
| | Acrolein | 2 | 1999 | 23 | 0.020 |
Why?
| | cdc25 Phosphatases | 1 | 2008 | 12 | 0.020 |
Why?
| | Isomerism | 1 | 2008 | 43 | 0.020 |
Why?
| | Transplantation, Heterologous | 1 | 2008 | 181 | 0.020 |
Why?
| | Microcirculation | 1 | 2008 | 135 | 0.020 |
Why?
| | Drug Design | 1 | 2009 | 148 | 0.020 |
Why?
| | Mycobacterium | 1 | 2009 | 103 | 0.020 |
Why?
| | Metallothionein | 1 | 1988 | 24 | 0.020 |
Why?
| | Molecular Conformation | 1 | 2008 | 135 | 0.020 |
Why?
| | Cyclins | 1 | 2008 | 78 | 0.020 |
Why?
| | Peptides | 1 | 2013 | 848 | 0.020 |
Why?
| | Enzyme Induction | 1 | 1988 | 84 | 0.020 |
Why?
| | Cell Differentiation | 1 | 1995 | 1700 | 0.020 |
Why?
| | Rats, Inbred Strains | 1 | 1988 | 362 | 0.020 |
Why?
| | Leukemia P388 | 1 | 2007 | 7 | 0.020 |
Why?
| | Amino Acids | 1 | 1991 | 448 | 0.020 |
Why?
| | Cells, Cultured | 3 | 1994 | 3885 | 0.020 |
Why?
| | Dominican Republic | 1 | 2007 | 18 | 0.020 |
Why?
| | Rats, Inbred F344 | 1 | 1988 | 241 | 0.020 |
Why?
| | Mice, Nude | 1 | 2008 | 630 | 0.020 |
Why?
| | DNA Topoisomerases, Type I | 1 | 1987 | 16 | 0.020 |
Why?
| | Inhibitor of Apoptosis Proteins | 1 | 2007 | 42 | 0.020 |
Why?
| | Angiogenesis Inhibitors | 1 | 2008 | 214 | 0.020 |
Why?
| | Fluorescence | 1 | 2007 | 148 | 0.020 |
Why?
| | Biological Assay | 1 | 2007 | 112 | 0.020 |
Why?
| | Capsules | 1 | 2006 | 36 | 0.020 |
Why?
| | Antigens, Viral | 1 | 2007 | 176 | 0.020 |
Why?
| | Species Specificity | 1 | 1988 | 542 | 0.020 |
Why?
| | Blotting, Northern | 2 | 1998 | 193 | 0.020 |
Why?
| | Fluorescent Antibody Technique | 1 | 2007 | 397 | 0.020 |
Why?
| | Mice, Inbred BALB C | 1 | 2009 | 1143 | 0.020 |
Why?
| | Glutathione | 1 | 1988 | 293 | 0.020 |
Why?
| | Solubility | 1 | 2006 | 223 | 0.020 |
Why?
| | Plant Leaves | 1 | 2007 | 110 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2008 | 498 | 0.020 |
Why?
| | Caspases | 1 | 2007 | 245 | 0.020 |
Why?
| | Microtubule-Associated Proteins | 1 | 2007 | 174 | 0.020 |
Why?
| | Amphotericin B | 1 | 2005 | 29 | 0.020 |
Why?
| | Cell Death | 1 | 2007 | 322 | 0.020 |
Why?
| | Biological Transport | 1 | 2006 | 373 | 0.020 |
Why?
| | Plant Components, Aerial | 1 | 2005 | 3 | 0.020 |
Why?
| | Drosophila | 1 | 1987 | 133 | 0.020 |
Why?
| | Double-Blind Method | 1 | 2010 | 1660 | 0.020 |
Why?
| | Social Work | 1 | 2006 | 74 | 0.020 |
Why?
| | Culture | 1 | 2006 | 124 | 0.020 |
Why?
| | Telephone | 1 | 2006 | 152 | 0.020 |
Why?
| | Pilot Projects | 1 | 2010 | 1373 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2007 | 923 | 0.020 |
Why?
| | Flow Cytometry | 1 | 2008 | 1083 | 0.010 |
Why?
| | Cognition Disorders | 1 | 2009 | 476 | 0.010 |
Why?
| | Coumarins | 1 | 2004 | 20 | 0.010 |
Why?
| | Fluorouracil | 1 | 2004 | 152 | 0.010 |
Why?
| | Models, Molecular | 1 | 2008 | 1369 | 0.010 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2004 | 332 | 0.010 |
Why?
| | Methotrexate | 1 | 2004 | 226 | 0.010 |
Why?
| | Poverty | 1 | 2006 | 442 | 0.010 |
Why?
| | Social Support | 1 | 2006 | 528 | 0.010 |
Why?
| | 14-3-3 Proteins | 1 | 2000 | 13 | 0.010 |
Why?
| | Colorectal Neoplasms | 1 | 2006 | 615 | 0.010 |
Why?
| | Reproducibility of Results | 1 | 2007 | 2762 | 0.010 |
Why?
| | Cations | 1 | 2000 | 78 | 0.010 |
Why?
| | Ethacrynic Acid | 1 | 1998 | 1 | 0.010 |
Why?
| | Brain Neoplasms | 1 | 2006 | 979 | 0.010 |
Why?
| | Absorption | 1 | 1998 | 52 | 0.010 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2006 | 961 | 0.010 |
Why?
| | Chemistry, Pharmaceutical | 1 | 1998 | 98 | 0.010 |
Why?
| | Cross-Linking Reagents | 1 | 1998 | 181 | 0.010 |
Why?
| | Adult | 1 | 1999 | 30542 | 0.010 |
Why?
| | Immune Sera | 1 | 1997 | 79 | 0.010 |
Why?
| | Osteomyelitis | 1 | 1998 | 105 | 0.010 |
Why?
| | Infant | 1 | 2010 | 7959 | 0.010 |
Why?
| | Oxidants | 1 | 1997 | 112 | 0.010 |
Why?
| | Immunoblotting | 1 | 1997 | 283 | 0.010 |
Why?
| | Child, Preschool | 1 | 2010 | 9111 | 0.010 |
Why?
| | Rabbits | 1 | 1997 | 733 | 0.010 |
Why?
| | Aged, 80 and over | 1 | 2006 | 6345 | 0.010 |
Why?
| | Lung Neoplasms | 1 | 2006 | 2177 | 0.010 |
Why?
| | Growth Substances | 1 | 1994 | 138 | 0.010 |
Why?
| | Activating Transcription Factors | 1 | 1993 | 2 | 0.010 |
Why?
| | Epithelium | 1 | 1994 | 295 | 0.010 |
Why?
| | Baculoviridae | 1 | 1992 | 44 | 0.010 |
Why?
| | Zinc Fingers | 1 | 1992 | 43 | 0.010 |
Why?
| | Moths | 1 | 1992 | 35 | 0.010 |
Why?
| | Rats, Sprague-Dawley | 1 | 1997 | 2218 | 0.010 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinases | 1 | 1992 | 172 | 0.010 |
Why?
| | Adolescent | 1 | 2010 | 17837 | 0.010 |
Why?
| | Genetic Vectors | 1 | 1992 | 289 | 0.010 |
Why?
| | Swine | 1 | 1994 | 700 | 0.010 |
Why?
| | Child | 1 | 2010 | 18407 | 0.010 |
Why?
| | Zinc | 1 | 1993 | 260 | 0.010 |
Why?
| | Protein Processing, Post-Translational | 1 | 1992 | 399 | 0.010 |
Why?
| | Aged | 1 | 2006 | 19068 | 0.000 |
Why?
| | Epithelial Cells | 1 | 1994 | 950 | 0.000 |
Why?
| | Middle Aged | 1 | 2006 | 26732 | 0.000 |
Why?
| | Mutation | 1 | 1993 | 3345 | 0.000 |
Why?
|
|
Kroll's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|